0

Purchase Short-Term Access

Review: Dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes
Saurav Chatterjee, MD; Sanjay Chatterjee, MD


Annals of Internal Medicine 2013;158:JC8. doi:10.7326/0003-4819-158-8-201304160-02008

Purchase Online access to this article for 24 hours
Buy Now

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)